| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.256 | 1.338 | 2.747 | 0 | 10.737 | 3.763 | 5.408 | 21.211 | 2.001 | 4.724 |
| Total Income - EUR | 1.256 | 1.338 | 2.747 | 0 | 10.737 | 4.039 | 5.684 | 21.467 | 2.257 | 4.979 |
| Total Expenses - EUR | 1.140 | 1.331 | 1.376 | 590 | 1.420 | 2.326 | 4.221 | 5.673 | 2.855 | 5.264 |
| Gross Profit/Loss - EUR | 116 | 7 | 1.372 | -590 | 9.317 | 1.712 | 1.463 | 15.795 | -598 | -285 |
| Net Profit/Loss - EUR | 89 | 6 | 1.289 | -590 | 8.995 | 1.603 | 1.301 | 15.171 | -598 | -394 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Biotechnology Consulting Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 122 | 121 | 119 | 117 | 114 | 1.755 | 1.464 | 1.203 | 935 | 666 |
| Current Assets | 412 | 507 | 1.524 | 953 | 10.424 | 3.518 | 5.613 | 18.250 | 9.644 | 10.165 |
| Inventories | 0 | 22 | 50 | 125 | 122 | 209 | 1.476 | 1.591 | 1.773 | 1.763 |
| Receivables | 337 | 0 | 219 | 215 | 10.210 | 507 | 718 | 14.526 | 3.806 | 3.968 |
| Cash | 74 | 485 | 1.255 | 614 | 92 | 2.803 | 3.419 | 2.133 | 4.065 | 4.433 |
| Shareholders Funds | 134 | 138 | 1.425 | 808 | 9.788 | 1.695 | 2.958 | 15.212 | 7.686 | 7.249 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 400 | 490 | 218 | 262 | 751 | 1.577 | 2.396 | 2.771 | 1.683 | 2.633 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 2.001 | 1.722 | 1.470 | 1.210 | 948 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7490 - 7490" | |||||||||
| CAEN Financial Year |
7490
|
|||||||||
Comments - Biotechnology Consulting Srl